Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United States
Los Angeles General Medical Center, Los Angeles, California USC / Norris Comprehensive Cancer Center, Los Angeles, California UCHealth University of Colorado Hospital, Aurora, Colorado University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida University of Chicago Comprehensive Cancer Center, Chicago, Illinois UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois University of Chicago Medicine-Orland Park, Orland Park, Illinois Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland Dana-Farber Cancer Institute, Boston, Massachusetts University of Michigan Rogel Cancer Center, Ann Arbor, Michigan Washington University School of Medicine, St Louis, Missouri Siteman Cancer Center-South County, St Louis, Missouri University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania M D Anderson Cancer Center, Houston, Texas University of Virginia Cancer Center, Charlottesville, Virginia